The present invention relates to non-steroidal progesterone receptor modulators of the general formula I
the use of the progesterone receptor modulators for producing medicaments, and pharmaceutical compositions which comprise these compounds.
The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.
The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte.
A compound represented by the formula (I):
wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.
CYANOQUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM
申请人:Prien Olaf
公开号:US20080108627A1
公开(公告)日:2008-05-08
The present invention relates to a quinoline derivative having the general formula (A):
in which R
1
, R
2
, X, Y and Z are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
Quinoline derivative, its use, production and pharmaceutical agents containing the latter
申请人:Schwede Wolfgang
公开号:US20060167035A1
公开(公告)日:2006-07-27
This invention relates to a quinoline derivative with general formula A
in which R
1
, R
2
, R
3
, X, Y, Z and A are indicated in the description and the claims, the use of the compounds of general formula A for treating various diseases as well as the production of compounds of general formula A.
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
申请人:Dumas Jacques
公开号:US20050038031A1
公开(公告)日:2005-02-17
This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.